Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx is well positioned as a commercial-stage biopharmaceutical company built around tenapanor, with IBSRELA for IBS-C and XPHOZAH for CKD patients on dialysis, both addressing large populations with substantial unmet need and limited competition. The positive outlook is supported by the company’s differentiated, non-secretagogue mechanism, strong white-space opportunity in the ~11.5 million-adult IBS-C market and the ~34 million-patient CIC market, plus the potential for broader prescribing as CIC and IBS-C symptoms overlap. Despite 2Q26 reimbursement headwinds and leadership turnover, the long-term thesis remains intact because specialty pharmacy channels, high adherence potential versus phosphate binders, and continued prescription growth could drive a rebound as execution improves.

Ardelyx is facing a fragile investment case because its commercial trajectory depends on regulatory flexibility, favorable labeling, and reimbursement structures that can shift against it at any time. Even with IBSRELA and XPHOZAH, the company only captures revenue from non-Medicare patients, while its access strategy relies on patient assistance and physician agnosticism rather than durable payer certainty, which can limit monetization quality. The departure of Chief Commercial Officer Eric Foster effective 8/28/26 adds execution risk, and the cited DCF assumptions of a 17.5% discount rate and -2.0% terminal growth rate reflect elevated uncertainty, pricing pressure, and the standard clinical and regulatory risks facing the franchise.